Site Editor

Thomas Flaig, MD

Advertisement
Advertisement

AACR 2022: Use of Tumor-Derived DNA From Urine and Plasma Samples to Predict Outcomes in Bladder Cancer

By: Kayci Reyer
Posted: Tuesday, April 12, 2022

According to research presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 (Abstract 1275/22), DNA derived from muscle-invasive bladder tumors may be more likely to appear in urine samples than in plasma samples. Relationships between the clearance of tumor-derived DNA levels and treatment outcomes were noted across sample types, in this analysis via deep targeted sequencing of both urine and plasma samples.

“Interestingly, we show that tumor-derived DNA dynamics in urine supernatants might better reflect the local tumor environment, and plasma-based tumor-derived DNA better reflects outcomes following surgery (ie, disease dissemination),” noted Lars Dyrskjøt, PhD, of Aarhus University Hospital, Denmark, and colleagues.

The study included 92 patients with localized muscle-invasive bladder cancer who had undergone treatment with neoadjuvant chemotherapy followed by radical cystectomy. Precystectomy samples of plasma (n = 167), urine supernatants (n = 281), and urine pellets (n = 114) were collected and analyzed via deep targeted sequencing. An additional 288 plasma samples associated with 56 patients from a previous study were evaluated.

An association was noted between tumor-derived DNA levels in pairs of supernatants and pellets from urine samples, with higher DNA levels occurring in pellets. About 20% of plasma samples had observable DNA versus 63% and 68% of supernatant and pellet samples, respectively. The clearance of tumor-derived DNA in urine supernatants appeared to be significantly associated with neoadjuvant chemotherapy outcomes; however, clearance of tumor-derived DNA in plasma samples was significantly associated with recurrence-free survival (P < .001) but not for urine supernatants (P = .06) and urine pellets (P = .53).

Disclosure: The study authors reported no conflicts of interest.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.